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Objectives. To examine trajectories of CD8 + T-cell counts before and after combination antiretroviral therapy (cART) in human immunodeficiency virus (HIV)-infected individuals and associations with mortality.
Methods. CD8 + T-cell counts were measured in 3882 HIV-infected individuals who received care in Copenhagen during [1995] [1996] [1997] [1998] [1999] [2000] [2001] [2002] [2003] [2004] [2005] [2006] [2007] [2008] [2009] [2010] [2011] [2012] . Reference values were obtained from 1230 persons from the background population. Mortality rate ratios were estimated by Poisson regression.
Results. CD8 + T-cell counts were elevated during untreated HIV infection and remained elevated through 10 years of cART. A slight drop of 130 cells/µL (interquartile range, −160 to 410 cells/μL) in the median CD8 + T-cell count was observed after cART initiation. CD8 + T-cell counts stabilized at approximately 900 cells/µL (95th percentile of the background population, 835 cells/µL). Markedly elevated CD8 + T-cell counts at cART initiation were associated with a poor increase in the CD4 + T-cell count (relative risk, 2.22; 95% confidence interval [CI], 1.
42-3.48). Individuals with a CD8
+ T-cell count of <500 cells/µL 1 year after cART initiation had an increased mortality rate (mortality rate ratio, 1.73; 95% CI, 1.29-2.32) and a higher proportion of deaths attributable to AIDSrelated conditions, compared with individuals with CD8 + T-cell counts of ≥500 cells/µL. After receiving cART for 10 years, a CD8 + T-cell count of >1500 cells/µL was associated with increased non-AIDS-related mortality (mortality rate ratio, 1.82; 95% CI, 1.09-3.22), compared with a CD4 + T-cell count of 500-1500 cells/µL.
Conclusions. CD8
+ T-cell counts are elevated during HIV infection and do not normalize despite long-term cART. Low CD8 + T-cell counts are associated with increased AIDS-related mortality. Marked elevations in CD8 + T-cell counts after long-term cART are associated with increased non-AIDS-related mortality.
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Human immunodeficiency virus (HIV) infection leads to perturbations of T-cell homeostasis and a skewed distribution of T-cell subsets [1] . In contrast to the gradual decrease in CD4 + T-cell count seen in the majority of untreated HIV-infected individuals, CD8 + T-cell counts are elevated in most cases until HIV infection becomes severe, when CD4 + and CD8 + T-cell counts are depleted. While the majority of HIV-infected individuals achieve normal CD4 + T-cell counts after long-term receipt of combination antiretroviral therapy (cART) [2] , there are continuous quantitative, qualitative, and functional defects in the CD8 + T-cell compartment despite successful treatment, although some of these defects may be reversed by early initiation of cART [3] [4] [5] [6] .
The elevation of CD8 + T-cell counts during untreated HIV infection is presumably caused by increased peripheral CD8 + T-cell proliferation due to antigen stimulation and immune activation, but the mechanisms are not well understood [7] . All CD8 + T-cell subsets are increased in HIV-infected individuals, but the proportion of terminally differentiated CD8 + T cells are disproportionately elevated, and the proportion of naive cells is reduced [8] [9] [10] .
The clinical implications of abnormal CD8 + T-cell counts during HIV infection have not been fully elucidated. Recent studies have shown that a low ratio of CD4 + to CD8 + T cells among treated HIV-infected individuals is associated with increased morbidity and mortality [11, 12] . The homeostasis of the CD4 + and CD8 + T-cell compartments are regulated differentially [5, 7] ; thus, CD8 + T-cell counts may predict prognosis independently of CD4 + T-cell counts.
The aim of the present study was to describe changes in CD8 + T-cell counts during untreated HIV infection and during long-term cART in a large population-based cohort of HIVinfected individuals and to examine associations with CD4 + T-cell count increases and mortality.
METHODS

Data Sources
The Danish HIV Cohort Study, described in details elsewhere [13] , is a population-based nationwide cohort study of all HIV-infected individuals who have received care in Danish HIV centers after 1 January 1995. CD4 + and CD8 + T-cell count and HIV RNA load measurements are extracted electronically from laboratory data files. Data on vital status and migration and causes of death were retrieved from the Danish Civil Registration System [14] and the National Registry of Causes of Death.
References values for CD8 + T-cell counts were obtained from a sample of 1230 persons from the background population. This group consisted of healthy staff, blood donors, and stem-cell donors. CD4 + and CD8 + T-cell counts were measured by the single platform lyse-no-wash procedure, using Becton-Dickinson TRUcount beads and monoclonal antibodies against CD3, CD4, and CD8.
Study Population
We included all HIV-infected individuals aged ≥16 years at diagnosis, who received care in HIV centers in Copenhagen in the period 1 January 1995 to 31 December 2012. Individuals with no available data on CD8 + T-cell counts were excluded from the study. For specific analyses we included subsets of this population who fulfilled specified criteria as described in detail later. 
Statistics
Ethics
The study was approved by the Danish Data Protection Agency. Ethics approval and individual consent are not required by Danish legislation governing this type of study.
RESULTS
A total of 4191 HIV-infected adults were followed in HIV centers in Copenhagen during the study period. Of these, 309 individuals were excluded because of lack of data on CD8 + T-cell counts. We thus included 3882 individuals, of whom 3060 (79%) were male; the median age at the time of the first CD8 + T-cell count mea- ≥200 cells/µL. There were only slight differences between other subgroups: CD8 + T-cell counts were higher among MSM, compared with heterosexual men and women, and among individuals aged ≥50 years, compared with those aged <50 years. CD8 + T-cell counts were significantly higher than in the background population in all subgroups (P < .001 for all comparisons). There was no correlation between CD8 + T-cell count and HIV RNA load (ρ = −0.01; P = .72).
Distribution of CD8 + T-Cell Counts at the Start of cART
CD8 + T-Cell Counts and Other Viral Infections
There were no significant associations between CD8 + T-cell count and HBV or HCV coinfection at the time of cART initiation (Table 1) . Individuals who were seropositive for CMV had higher CD8 + T-cell counts than those who were seronegative, but the difference was small and not statistically significant in multivariate analysis. A year after cART initiation, when 71% of the HIVinfected individuals had an HIV RNA load of <40 copies/mL, CMV-seropositive status was associated with a higher median In analyses of trajectories of CD8 + T-cell counts, we included 865 individuals for whom CD8 + T-cell counts were available at least 2 years before and 1 year after cART. A total of 28 442 CD8 + T-cell counts were measured for these patients, with a median interval of 98 days (IQR, 83-127 days). CD8 + T-cell counts were stable during chronic, untreated HIV infection. Within the first 2 years after cART initiation, the median change in CD8 + T-cell count was −130 cells/µL (IQR, −160 to 410 cells/μL; Figure 1 ). CD8 + T-cell counts remained high, compared with data for the background population, with no change the following 8 years (median change, 0 cells/µL; 95% confidence interval [CI] , −240 to 250 cells/µL). There was a strong correlation between CD8 + T-cell counts 2 years before cART initiation and 5 years after cART initiation (ρ = 0.42; P < .001).
If individuals without serial CD8 + T-cell count measurements 2 years before and 1 year after cART initiation were included in analyses (n = 2284), the median CD8 + T-cell count at cART initiation was lower (Table 1) , while CD8 + T-cell counts at other time points were not significantly different (data not shown). The lower CD8 + T-cell count at cART initiation was explained by inclusion of individuals who had advanced HIV disease and severe lymphopenia at the time of HIV diagnosis and cART initiation. Figure 2 shows the distributions of CD4 + and CD8 + T-cell counts at cART initiation and 10 years thereafter. The variance in CD8 + T-cell counts decreased, but the mean changed only little after cART initiation, which is in contrast to the significant increase in both mean and variance of CD4 + T-cell counts. Even after 10 years of cART, CD8 + T-cell counts were significantly higher and CD4 + T-cell counts lower among HIV-infected individuals, compared with the background population (P < .001 in both analyses). Changes in the ratio of CD4 + to CD8 + T-cell counts during the first 2 years of cART had a closer correlation to changes in CD4 + T-cell counts than changes in CD8 + T-cell counts (ρ = 0.49 [P < .001] and ρ = 0.39 [P < .001], respectively).
We assessed CD8 + T-cell counts by viral load 1 year after cART initiation and found no differences in CD8 + T-cell counts between different viral load strata (Supplementary Figure 1) .
Trajectories of CD8 + T-Cell Counts, by Immune Status Before cART Initiation
To examine the impact of immune status before cART initiation, we analyzed CD8 + T-cell count trajectories from the time of cART initiation onward in 3 separate analyses in which HIV-infected patients were grouped on the basis of their last CD4 + T-cell count, their last CD8 + T-cell count, and their total lymphocyte count before the start of cART (Figure 3A-C) . The measurement by which patients were grouped was not included in analyses, to avoid regression toward the mean. In these analyses, we included patients who had CD8 + T-cell count measurements before and at the time of cART initiation and at least once thereafter (n = 1235). In all 3 analyses, there was a tendency toward stabilization of CD8 + T-cell counts at a level of approximately 900 cells/µL 1-2 years after cART initiation. Within the first year of cART initiation, CD8 + Tcell counts dropped among individuals with higher baseline CD8 + T-cell counts, whereas they increased among individuals with lower baseline CD8 + T-cell counts. This trend was similar in the 3 analyses.
CD8 + T-Cell Counts and Increases in CD4 + T-Cell Counts After cART Initiation
Among individuals with a viral load of <400 copies/mL 1 year after cART, the median increase in CD4 + T-cell count during the first year of cART was significantly lower among individuals with a CD8 + T-cell count of >2000 at cART initiation, compared with those with a CD8 + T-cell count of ≤2000 cells/µL 
CD8 + T-Cell Counts and Mortality
The association between CD8 + T-cell count and risk of death changed over time of cART receipt ( Table 2) . Individuals with CD8 + T-cell counts of <500 cells/µL at the time of cART initiation had increased mortality, compared with those with CD8 + T-cell counts of 500-1500 cells/µL. Both individuals with CD8 + T-cell counts of <500 cells/µL and those with CD8 + T-cell counts of >2000 cells/µL 1 year after cART initiation had increased mortality. Individuals with CD8 + T-cell counts of >1500 cells/µL 10 years after cART initiation had increased mortality, whereas low CD8 + T-cell counts were not In analyses restricted to individuals with a fatal outcome, time to death was markedly shorter for individuals with CD8 + T-cell counts of <500 cells/µL, compared with those with higher CD8 + T-cell counts (Table 2) , and a higher proportion of deaths were AIDS related. Among individuals with CD8 + T-cell counts of <500 cells/µL at cART initiation, 24 deaths (22% of all deaths) were AIDS related, compared with 36 deaths (13%) among those with CD8 + T-cell counts of ≥500 cells/µL (P = .04). Among individuals with CD8 + T-cell counts of <500 cells/µL 1 year after cART initiation, the corresponding values were 15 (24%) and 20 (8%), respectively (P < .01). There were no AIDS-related deaths >10 years after cART initiation.
To examine whether associations between CD8 + T-cell counts and mortality were explained by virological failure, we reanalyzed the data while censoring individuals at the time of virological failure (defined as an HIV RNA load of >1000 copies/mL >180 days after cART initiation). Results did not differ significantly from results of the original analyses (Supplementary Table 1 ). We repeated the analyses by using total lymphocyte counts instead of CD8 + T-cell counts. Findings were quite different from findings of associations between CD8 + T-cell counts and mortality. Low total lymphocyte counts were associated with increased mortality, and the association became stronger after long-term cART receipt, while there was no association between high total lymphocyte count and mortality (Table 3) .
DISCUSSION
In this study examining trajectories of CD8 + T-cell counts in HIV-infected individuals before and after long-term cART, we found that CD8 + T-cell counts were significantly elevated in untreated HIV-infected individuals and decrease only slightly after cART initiation. CD8 + T-cell counts were elevated in all subgroups examined. Individuals with markedly elevated CD8 + T-cell counts at treatment initiation had an increased risk of having a poor CD4 + T-cell count gain. After cART initiation, CD8 + T-cell counts converged toward levels above the 95th percentile in the background population and remained there despite >10 years of cART. Low CD8 + T-cell counts within the first year after cART initiation were associated with increased mortality, with a high proportion of AIDS-related deaths. After long-term cART, markedly elevated CD8 + T-cell counts were associated with increased non-AIDS-related mortality. The observed lack of normalization of CD8 + T-cell counts after long-term cART is somewhat surprising, since previous studies have shown that CD8 + T-cell proliferation is correlated with HIV replication and decreases markedly after initiation of cART [15, 16] , and is in contrast to the fact that the majority of HIV-infected patients experience CD4 + T-cell count recovery toward levels comparable to those of the background population. CD8 + T-cell counts were slightly higher in MSM and in individuals with CMV infection. These findings are similar to results of previous studies [17, 18] and indicate that ongoing infections other than HIV infection may exacerbate elevations of CD8 + T-cell counts; however, their contribution first becomes evident once HIV replication is controlled.
There was a clear association between CD8 + T-cell counts before and after cART initiation. Previous studies have shown that CD8 + T-cell counts correlate with proviral DNA [19] and that the increase in CD8 + T-cell counts during primary HIV infection coincides with expansion of the HIV reservoir [20, 21] . Together, these findings could suggest that the CD8 + T-cell count reflects the size of the viral reservoir. In contrast, we found no correlation between CD8 + T-cell counts and HIV RNA loads.
Our finding of an association between high CD8 + T-cell counts and a poor CD4 + T-cell count response to cART is in line with previous studies showing that poor CD4 + T-cell count gain is associated with hyperactivation of CD8 + T cells, increased rates of peripheral CD8 + T-cell proliferation, and depletion of naive cells [22] .
HIV-infected individuals with relatively low CD8 + T-cell counts during the first year of cART had increased mortality. Low CD8 + T-cell counts were associated with increased mortality, independently of age and CD4 + T-cell count. The association persisted even when individuals were censored at virological failure and is therefore not explained by uncontrolled HIV replication. CD8 + T cells have important functions in the control of infections and for immune surveillance. CD8 + T cells inhibit and kill tumor cells through production of interferon γ and through cytotoxic effects [23] . Thus, depletion of CD8 + T cells may cause an increased risk of cancer. Approximately one The reference value of 1000-2000 cells/µL for total lymphocyte count corresponded to the 25th-75th percentile, and a total lymphocyte count of >2600 cells/µL corresponded to the 90th percentile in the HIV-infected population at start of cART.
fourth of the deaths among HIV-infected individuals with low CD8 + T-cell counts during the first year of cART occurred within a year. This reflects the high risk of AIDS-related events among individuals with severe immunodeficiency at cART initiation. It is possible that redistribution of lymphocytes from blood to tissues with ongoing pathological processes is part of the explanation for the observed association between low CD8 + T-cell counts and increased short-term mortality.
Markedly elevated CD8 + T-cell counts after long-term cART were associated with a moderate increase in non-AIDS-related mortality. An association between high CD8 + T-cell counts and increased mortality has previously been observed in HIVnegative populations [24, 25] . Elevated CD8 + T-cell counts are associated with immune activation [26] . Whether there is an association between immune activation and an increased risk of non-AIDS-related mortality in the long term (eg, deaths due to cardiovascular disease, cancer, and liver disease) needs to be explored in future studies. The present study is limited in that we did not have data on the subsets of CD8 + T cells or proportions of activated CD8 + T cells. Strengths of the study include the large study population with data on CD8 + T-cell counts and long-term follow-up.
We conclude that CD8 + T-cell counts are continuously elevated in HIV-infected individuals and not normalized despite 10 years of cART. Individuals with CD8 + T-cell counts below the median of the background population during the first year of cART have increased mortality, with an elevated risk of AIDS-related death within a year. Marked elevations in CD8 + T-cell counts after long-term cART are associated with increased non-AIDS-related mortality.
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